assembly Bill A2030

Signed By Governor
2021-2022 Legislative Session

Relates to medication assisted treatment for substance use disorders

download bill text pdf

Sponsored By

Current Bill Status - Signed by Governor

  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed by Governor

Your Voice

do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

view actions (13)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Dec 22, 2021 signed chap.720
Dec 10, 2021 delivered to governor
Jun 03, 2021 returned to assembly
passed senate
3rd reading cal.1294
substituted for s649a
May 24, 2021 referred to finance
delivered to senate
passed assembly
May 13, 2021 advanced to third reading cal.347
May 11, 2021 reported
Feb 02, 2021 reported referred to ways and means
Jan 14, 2021 referred to health

Votes

view votes

Jun 3, 2021 - floor Vote

A2030
55
8
floor
55
Aye
8
Nay
0
Absent
0
Excused
0
Abstained
show floor vote details

Floor Vote: Jun 3, 2021

aye (55)
nay (8)

Co-Sponsors

view additional co-sponsors

A2030 (ACTIVE) - Details

See Senate Version of this Bill:
S649
Law Section:
Social Services Law
Laws Affected:
Amd §§365-a & 364-j, Soc Serv L; amd §273, Pub Health L
Versions Introduced in 2019-2020 Legislative Session:
A9634, S7699

A2030 (ACTIVE) - Summary

Relates to medication assisted treatment for substance abuse disorders; prohibits prior authorization.

A2030 (ACTIVE) - Bill Text download pdf 

 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   2030
 
                        2021-2022 Regular Sessions
 
                           I N  A S S E M B L Y
 
                             January 14, 2021
                                ___________
 
 Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN,
   SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on
   Health
 
 AN  ACT  to  amend the social services law and the public health law, in
   relation to medication for the treatment of substance use disorders

   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Subdivision 2 of section 365-a of the social services law
 is amended by adding a new paragraph (gg) to read as follows:
   (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG  ACTING  INJECTABLE
 NALTREXONE  FOR  DETOXIFICATION  OR MAINTENANCE TREATMENT OF A SUBSTANCE
 USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES-
 SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.    SUCH
 MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI-
 ZATION MANDATE.
   §  2. Subdivision 26-b of section 364-j of the social services law, as
 added by section 4 of part B of chapter 69  of  the  laws  of  2016,  is
 amended to read as follows:
   26-b. Managed care providers shall not require prior authorization for
 [an  initial  or  renewal  prescription  for buprenorphine or injectable
 naltrexone  for  detoxification  or  maintenance  treatment  of   opioid
 addiction  unless  the prescription is for a non-preferred or non-formu-
 lary form of the drug or as otherwise required by section 1927(k)(6)  of
 the  Social  Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG
 ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT
 OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO  GENERALLY  ACCEPTED
 NATIONAL  PROFESSIONAL  GUIDELINES  FOR THE TREATMENT OF A SUBSTANCE USE
 DISORDER.
   § 3. Subdivision 10 of section  273  of  the  public  health  law,  as
 amended  by  section  7 of part GG of chapter 56 of the laws of 2020, is
 amended to read as follows:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.